» Download Public Reports
12 reports
- Country report
- October 2009
- 6 pages
... embryonic stem cells (hescs). Honda inc. Tokyo - honda motor co. (Hmc) on thursday took the wraps off a motorized unicycle that is controlled by simply shifting one's body weight in the desired direction ...
September 2010
... And conditions. And holding an important key to such innovations would be adult stem cells, which are taken from mature tissue, as they could theoretically be taken from patients, grown in culture ...
March 2011
... Believe gene therapy will emerge as a complementary medication to existing therapies. Treatment using multiple genes will likely become possible; moreover, there should be no need for gene therapy ...
March 2011
... Are under development in the u.S., 3) The r&d progress for biobetters and biosimilars, and 4) the sales performance of cartistem (an umbilical cord blood stem cell therapy). February 13, 2012 company ...
September 2011
... Biotech. 7 Healthcare market entry by conglomerates company business business developments samsung samsung electronics stem-cells - begin research on new medical technology that converges ...
September 2011
... Blood (stem cells) ability to migrate to area of injury/defect source to treat adult diseases cerebral palsy pediatric diabetes 1.Cord blood is blood that remains in the placenta and in the attached ...
March 2012
... Engineering research products Standing as korea S leading biotech player, bioneer specializes in developing molecular diagnostic products, gene therapy drugs, and genetic engineering research products ...
April 2012
... Is a human keratinocyte line that rele- ases abnormal level of chemokines, including tarc, mdc, rantes, vascular endothelial growth factor, and eotaxin when stimulated with tnf- And ifn- . When released from ...
October 2011
... Developed, such as the optimization of nutrient medium [6], and culture conditions [7], and elicitation[8]. Accumulation of ra has been intensively investigated in suspension cultures of anchusa ...
» Purchase Premium Reports
(From $ 250 - $ 6 125)
7 reports
- $ 6 860
- Industry report
- May 2013
- by France Innovation Scientifique et Transfert
Many diseases such as cardiovascular disorders, diabetes or neurodegenerative diseases are the consequences of dysfunction of specific cells. Strategies were developed to repair or regenerate the damaged ...
May 2013
$ 4 060
Many diseases such as cardiovascular disorders, diabetes or neurodegenerative diseases are the consequences of dysfunction of specific cells. Strategies were developed to repair or regenerate the damaged ...
April 2013
$ 516
Product description The present Competitive Intelligence Report about G-CSF and GM-CSF product portfolios and R&D pipelines provides a competitor evaluation in the field of G-CSF & GM-CSF branded products ...
March 2013
$ 250
Summary CHA Bio & Diostech Co., Ltd. (CHA Bio & Diostech) is a bio technology company, based in South Korea. It develops advance biomedicine through applied life science and technology. The company's products ...